Published in Pharmacol Ther on June 08, 2010
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Resolvins and protectins in inflammation resolution. Chem Rev (2011) 3.09
Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67
Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries. Mol Pharmacol (2013) 1.03
Receptor-dependent and -independent immunomodulatory effects of phenol-soluble modulin peptides from Staphylococcus aureus on human neutrophils are abrogated through peptide inactivation by reactive oxygen species. Infect Immun (2012) 0.96
The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. Am J Pathol (2015) 0.90
Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem (2012) 0.89
Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem (2012) 0.87
Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1. J Mol Model (2011) 0.85
Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors. Mol Pharmacol (2010) 0.84
Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26). Br J Pharmacol (2013) 0.84
Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation through the FPRL1 receptor. Mucosal Immunol (2013) 0.83
Annexin A1 induces skeletal muscle cell migration acting through formyl peptide receptors. PLoS One (2012) 0.83
Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology (2014) 0.83
GPCR ontology: development and application of a G protein-coupled receptor pharmacology knowledge framework. Bioinformatics (2013) 0.82
Formyl peptide receptor as a novel therapeutic target for anxiety-related disorders. PLoS One (2014) 0.81
Targeting pro-resolution pathways to combat chronic inflammation in COPD. J Thorac Dis (2014) 0.81
Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages. PLoS One (2012) 0.80
The intricate role of mast cell proteases and the annexin A1-FPR1 system in abdominal wall endometriosis. J Mol Histol (2014) 0.80
Synthesis, HPLC enantioresolution, and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists. Chirality (2013) 0.79
Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists. Eur J Med Chem (2013) 0.79
Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives. Int Immunopharmacol (2015) 0.79
Protective effects of n-6 fatty acids-enriched diet on intestinal ischaemia/reperfusion injury involve lipoxin A4 and its receptor. Br J Pharmacol (2014) 0.79
Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2. Bioorg Med Chem (2014) 0.77
Effects of n-3 PUFAs on Intestinal Mucosa Innate Immunity and Intestinal Microbiota in Mice after Hemorrhagic Shock Resuscitation. Nutrients (2016) 0.77
2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists. Bioorg Med Chem (2016) 0.77
The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model. PLoS One (2014) 0.77
Identification of a novel recycling sequence in the C-tail of FPR2/ALX receptor: association with cell protection from apoptosis. J Biol Chem (2014) 0.76
De novo chemoattractants form supramolecular hydrogels for immunomodulating neutrophils in vivo. Bioconjug Chem (2014) 0.76
Marine Natural Product Inhibitors of Neutrophil-Associated Inflammation. Mar Drugs (2016) 0.75
Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. Oncoimmunology (2017) 0.75
Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nat Commun (2017) 0.75
Characterizing the anti-inflammatory and tissue protective actions of a novel Annexin A1 peptide. PLoS One (2017) 0.75
Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. J Immunol (2016) 0.75
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
Role of the immune system in chronic pain. Nat Rev Neurosci (2005) 4.10
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J (2002) 2.13
Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 2.01
Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J Immunol (2005) 1.68
Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67
Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood (2005) 1.62
Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood (2008) 1.61
Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood (2003) 1.60
Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest (2012) 1.57
Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem (2006) 1.55
Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52
Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol (2006) 1.52
Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A (2013) 1.49
Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. J Leukoc Biol (2005) 1.43
The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha -inhibitor-independent manner. J Biol Chem (2002) 1.39
Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum (2004) 1.39
NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A (2002) 1.36
A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J (2003) 1.30
Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol (2009) 1.30
Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation. Am J Pathol (2005) 1.27
Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A (2004) 1.26
Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol (2010) 1.26
FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J (2010) 1.23
Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation. FASEB J (2007) 1.22
Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol (2003) 1.21
A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am J Pathol (2003) 1.20
Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol (2008) 1.18
Melanocortin receptor signaling in RAW264.7 macrophage cell line. Peptides (2005) 1.16
Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum (2002) 1.15
Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J Leukoc Biol (2008) 1.14
Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest (2015) 1.13
Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J (2007) 1.12
Ligand-specific glucocorticoid receptor activation in human platelets. Blood (2005) 1.12
Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB J (2007) 1.11
Annexin-1 modulates T-cell activation and differentiation. Blood (2006) 1.10
Annexin 1 cleavage in activated neutrophils: a pivotal role for proteinase 3. J Biol Chem (2007) 1.10
Melanocortin 3 receptors control crystal-induced inflammation. FASEB J (2006) 1.08
An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem Inst Oswaldo Cruz (2005) 1.08
The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol (2012) 1.07
Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol (2008) 1.06
Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB J (2010) 1.06
Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct. FASEB J (2004) 1.05
Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis. EMBO Mol Med (2013) 1.05
Inhibitory effects of TSG-6 Link module on leukocyte-endothelial cell interactions in vitro and in vivo. Microcirculation (2004) 1.05
Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Curr Opin Pharmacol (2005) 1.04
Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One (2013) 1.04
The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. Am J Pathol (2011) 1.03
Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol (2008) 1.03
Endogenous galectins and the control of the host inflammatory response. J Endocrinol (2009) 1.03
Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int (2006) 1.02
Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties. Mol Cell Proteomics (2013) 1.02
Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci (2002) 1.02
Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model. Arthritis Rheum (2011) 1.01
Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J Immunol (2013) 1.00
Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J Immunol (2011) 1.00
Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Mol Cell Proteomics (2005) 1.00
Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur J Immunol (2007) 0.99
Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol (2009) 0.99
Functional and ultrastructural analysis of annexin A1 and its receptor in extravasating neutrophils during acute inflammation. Am J Pathol (2008) 0.99
Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion. FASEB J (2008) 0.98
Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One (2012) 0.98
Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. J Pharmacol Exp Ther (2007) 0.98
Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study. Eur J Pharmacol (2009) 0.98
A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood (2013) 0.98
A role for MC3R in modulating lung inflammation. Pulm Pharmacol Ther (2008) 0.97
Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci U S A (2002) 0.97
Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature. Blood (2010) 0.97
Chemokines as novel therapeutic targets in inflammatory diseases. Biochem Pharmacol (2002) 0.96
Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol (2010) 0.96
Impaired phagocytic mechanism in annexin 1 null macrophages. Br J Pharmacol (2006) 0.96
The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann Rheum Dis (2012) 0.96
A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects. J Pharmacol Exp Ther (2008) 0.95
A novel effect for annexin 1-derived peptide ac2-26: reduction of allergic inflammation in the rat. J Pharmacol Exp Ther (2005) 0.95
Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J Med Chem (2007) 0.94
Glucocorticoid upregulation of the annexin-A1 receptor in leukocytes. Biochem Biophys Res Commun (2006) 0.94
Stromal cell-derived factor 1 (CXCL12) induces human cell migration into human lymph nodes transplanted into SCID mice. J Immunol (2002) 0.94
Antiallergic cromones inhibit neutrophil recruitment onto vascular endothelium via annexin-A1 mobilization. Arterioscler Thromb Vasc Biol (2010) 0.94
[D-Trp8]-gamma-melanocyte-stimulating hormone exhibits anti-inflammatory efficacy in mice bearing a nonfunctional MC1R (recessive yellow e/e mouse). Mol Pharmacol (2006) 0.93
A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J Immunol (2007) 0.93
IL-17A increases ADP-induced platelet aggregation. Biochem Biophys Res Commun (2011) 0.92
Smooth muscle cells in human atherosclerosis: proteomic profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease. J Mol Cell Cardiol (2012) 0.92
Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function. Obesity (Silver Spring) (2013) 0.91
Attenuation of plasma annexin A1 in human obesity. FASEB J (2012) 0.91
The effect of galectins on leukocyte trafficking in inflammation: sweet or sour? Ann N Y Acad Sci (2012) 0.91
An essential role for mast cells as modulators of neutrophils influx in collagen-induced arthritis in the mouse. Lab Invest (2010) 0.91
Sphingosine-1-phosphate modulates vascular permeability and cell recruitment in acute inflammation in vivo. J Pharmacol Exp Ther (2011) 0.90
In vitro and in vivo induction of heme oxygenase 1 in mouse macrophages following melanocortin receptor activation. J Immunol (2005) 0.90
Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem (2012) 0.89
Controlling inflammation: a fat chance? J Exp Med (2005) 0.89
Stimulus-specific defect in the phagocytic pathways of annexin 1 null macrophages. Br J Pharmacol (2004) 0.89
Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation. FASEB J (2008) 0.88
Endogenous galectin-1 and acute inflammation: emerging notion of a galectin-9 pro-resolving effect. Am J Pathol (2011) 0.88
Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther (2003) 0.88
Modulation of experimental autoimmune encephalomyelitis by endogenous annexin A1. J Neuroinflammation (2009) 0.88